21 results on '"Mangili, Paola"'
Search Results
2. Real-world validation of Artificial Intelligence-based Computed Tomography auto-contouring for prostate cancer radiotherapy planning
- Author
-
Palazzo, Gabriele, Mangili, Paola, Deantoni, Chiara, Fodor, Andrei, Broggi, Sara, Castriconi, Roberta, Ubeira Gabellini, Maria Giulia, del Vecchio, Antonella, Di Muzio, Nadia G., and Fiorino, Claudio
- Published
- 2023
- Full Text
- View/download PDF
3. Knowledge-based automatic plan optimization for left-sided whole breast tomotherapy
- Author
-
Esposito, Pier Giorgio, Castriconi, Roberta, Mangili, Paola, Broggi, Sara, Fodor, Andrei, Pasetti, Marcella, Tudda, Alessia, Di Muzio, Nadia Gisella, del Vecchio, Antonella, and Fiorino, Claudio
- Published
- 2022
- Full Text
- View/download PDF
4. Residual intra-fraction error in robotic spinal stereotactic body radiotherapy without immobilization devices
- Author
-
Rossi, Eleonora, Fiorino, Claudio, Fodor, Andrei, Deantoni, Chiara, Mangili, Paola, Di Muzio, Nadia Gisella, Del Vecchio, Antonella, and Broggi, Sara
- Published
- 2020
- Full Text
- View/download PDF
5. 3023: ENRT vs MDT for prostate cancer lymph nodal relapses: a preliminary analysis
- Author
-
Fodor, Andrei, Brombin, Chiara, Giannini, Laura, Deantoni, Chiara Lucrezia, Torrisi, Miriam, Dell'Oca, Italo, Mangili, Paola, Rancoita, Paola Maria Vittoria, Midulla, Martina, Cozzarini, Cesare, Mapelli, Paola, Picchio, Maria, Vecchio, Antonella Del, Fiorino, Claudio, Di Serio, Mariaclelia Stefania, and Di Muzio, Nadia Gisella
- Published
- 2024
- Full Text
- View/download PDF
6. 2516: NTCP model of acute toxicity after whole breast irradiation: training and extended validation
- Author
-
Cicchetti, Alessandro, Vincenzi, Monica, Castriconi, Roberta, Mangili, Paola, Fodor, Andrei, Gabellini, Maria Giulia Ubeira, Chiara, Anna, Deantoni, Chiara, Midulla, Martina, Mori, Martina, Pasetti, Marcella, Palazzo, Gabriele, Tummineri, Roberta, Torrisi, Miriam, Rancati, Tiziana, Vecchio, Antonella del, Di Muzio, Nadia G, and Fiorino, Claudio
- Published
- 2024
- Full Text
- View/download PDF
7. 2276: Skin Dose-volume Predictors of Late Fibrosis-related Toxicity after Whole Breast Radiotherapy
- Author
-
Cicchetti, Alessandro, Fodor, Andrei, Mangili, Paola, Gabellini, Maria Giulia Ubeira, Chiara, Anna, Deantoni, Chiara, Mori, Martina, Midulla, Martina, Pasetti, Marcella, Tummineri, Roberta, Palazzo, Gabriele, Torrisi, Miriam, Rancati, Tiziana, Vecchio, Antonella del, Di muzio, Nadia Gisella, and Fiorino, Claudio
- Published
- 2024
- Full Text
- View/download PDF
8. 1723: Breast density histogram analysis: the role of fat in outcome prediction after Breast Radiotherapy
- Author
-
Mori, Martina, Belardo, Alfonso, Fodor, Andrei, Mangili, Paola, Palazzo, Gabriele, Ubeira-Gabellini, Mariagiulia, Tummineri, Roberta, Torrisi, Miriam, Vecchio, Antonella Del, Di Muzio, Nadia G, and Fiorino, Claudio A.
- Published
- 2024
- Full Text
- View/download PDF
9. Clinical Implementation of Knowledge-Based Automatic Plan Optimization for Helical Tomotherapy.
- Author
-
Castriconi, Roberta, Cattaneo, Giovanni Mauro, Mangili, Paola, Esposito, Piergiorgio, Broggi, Sara, Cozzarini, Cesare, Deantoni, Chiara, Fodor, Andrei, Di Muzio, Nadia G., Vecchio, Antonella del, and Fiorino, Claudio
- Abstract
To implement knowledge-based (KB) automatic planning for helical TomoTherapy (HTT). The focus of the first clinical implementation was the case of high-risk prostate cancer, including pelvic node irradiation. One hundred two HTT clinical plans were selected to train a KB model using the RapidPlan tool incorporated in the Eclipse system (v13.6, Varian Inc). The individually optimized KB-based templates were converted into HTT-like templates and sent automatically to the HTT treatment planning system through scripting. The full dose calculation was set after 300 iterations without any additional planner intervention. Internal (20 patients in the training cohort) and external (28 new patients) validation were performed to assess the performance of the model: Automatic HTT plans (KB-TP) were compared against the original plans (TP) in terms of organs at risk and planning target volume (PTV) dose–volume parameters and by blinded clinical evaluation of 3 expert clinicians. KB-TP plans were generally better than or equivalent to TP plans in both validation cohorts. A significant improvement in PTVs and rectum–PTV overlap dosimetry parameters were observed for both sets. Organ-at-risk sparing for KB-TP was slightly improved, which was more evident in the external validation group and for bladder and bowel. Clinical evaluation reported KB-TP to be better in 60% of cases and worse in 10% compared with TP (P <.05). The fully KB-based automatic planning workflow was successfully implemented for HTT planning optimization in the case of high-risk patients with prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized?
- Author
-
Fodor, Andrei, Brombin, Chiara, Mangili, Paola, Borroni, Fulvio, Pasetti, Marcella, Tummineri, Roberta, Zerbetto, Flavia, Longobardi, Barbara, Perna, Lucia, Dell'Oca, Italo, Deantoni, Chiara L., Deli, Aniko M., Chiara, Anna, Broggi, Sara, Castriconi, Roberta, Esposito, Pier Giorgio, Slim, Najla, Passoni, Paolo, Baroni, Simone, and Villa, Stefano L.
- Subjects
BREAST cancer ,CANCER patients ,INTRAOPERATIVE radiotherapy ,INTENSITY modulated radiotherapy ,ACCELERATED partial breast irradiation ,HORMONE receptors ,RADIOTHERAPY - Abstract
We report molecular subtype impact on 1325 early breast cancer (BCa) patients treated with whole breast hypofractionated (WBH) adjuvant forward-planned intensity modulated radiotherapy (F-IMRT) without boost. From 02/2009-05/2017 1325 patients with pTis-pT3, pNx-N1aM0 BCa who underwent breast conservation surgery were treated with WBHF-IMRT in our institute, to a total dose of 40 Gy/15 fractions, without boost. Median age: 62 (interquartile range-IQR-:51.14–70.53) years. Histology: 8% in situ carcinoma (ISC), 92% invasive tumors. Molecular subtypes (invasive tumors): 49.9% Luminal A, 33.1% Luminal B Her2 negative (−), 6.2% Luminal B Her2 positive (+), 3.6% Hormone Receptor (HR)- Her2+, 7.1% Triple negative (TNBC), and 0.2% HR+. Chemotherapy (CT) was prescribed in 28% of patients, hormonal therapy in 80.3%, monoclonal antibodies (MAb) in 86.8% of Luminal B Her2+ and 97.7% of HR- Her2+ patients. Median follow up was 72.43 (IQR: 44.63–104.13) months. The 5-year Kaplan-Meier estimates of local relapse-free survival (LRFS) was 97.8%, regional-(RRFS) 98.6%, loco-regional- (LRRFS) 96.9%, distant- (DRFS) 96.6%, disease-free survival (DFS) 94.8% and overall survival (OS) 95.5%. Considering molecular subtypes, 5-year LRFS was: 99.8% for Luminal A, 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 87.9% for HR- Her2+, 95.1% for TNBC and 99.1% for in situ carcinoma. While the overall estimated probability of LR within 5 years after WBHF-IMRT without boost is good (2.2%), molecular subtypes have a strong impact, despite MAb therapy in Her2+ patients, and CT for TNBC patients, and could be used as a parameter in deciding the boost prescription. • Hypofractionated three-weeks radiotherapy ensures good local control whitout boost. • In 1325 early stage breast cancers 5-year local relapse without boost was 2.2%. • Molecular subtypes have a strong impact on estimated probability of local relapse. • 5-year local control (LC) was 99.8% for Luminal A vs 87.9% for HR- Her2+. • 5-year LC was 96.7% for Luminal B Her2-, 94.1% for Luminal B Her2+, 95.1% for TNBC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Virtual Tangential-fields Arc Therapy (ViTAT) for whole breast irradiation: Technique optimization and validation.
- Author
-
Esposito, Pier Giorgio, Castriconi, Roberta, Mangili, Paola, Fodor, Andrei, Pasetti, Marcella, Di Muzio, Nadia G., Del Vecchio, Antonella, and Fiorino, Claudio
- Abstract
• ViTAT mimics the dose distribution of tangential fields (TF) plans. • Using 20° sectors of four arcs is needed to mimic the delivery of TF. • Better PTV homogeneity and lower dose to contralateral OARs are obtained. • Mean dose to ipsilateral OARs are unchanged; body integral dose reduced. • ViTAT may translate KB-models based on TF data into efficient automatic planning. To test the performances of a volumetric arc technique named ViTAT (Virtual Tangential-fields Arc Therapy) mimicking tangential field irradiation for whole breast radiotherapy. ViTAT plans consisted in 4 arcs whose starting/ending position were established based on gantry angle distribution of clinical plans for right and left-breast. The arcs were completely blocked excluding the first and last 20°. Different virtual bolus densities and thicknesses were preliminarily evaluated to obtain the best plan performances. For 40 patients with tumor laterality equally divided between right and left sides, ViTAT plans were optimized considering the clinical DVHs for OARs (resulting from tangential field manual planning) to constrain them: ViTAT plans were compared with the clinical tangential-fields in terms of DVH parameters for both PTV and OARs. Distal angle values were suggested in the ranges [220°,240°] for the right-breast and [115°,135°] for the left-breast cases; medial angles were [60°,40°] for the right side and [295°,315°] for the left side, limiting the risk of collision. The optimal virtual bolus had −500 HU density and 1.5 cm thickness. ViTAT plans generated dose distributions very similar to the tangential-field plans, with significantly improved PTV homogeneity. The mean doses of ipsilateral OARs were comparable between the two techniques with minor increase of the low-dose spread in the range 2–15 Gy (few % volume); contralateral OARs were slightly better spared with ViTAT. ViTAT dose distributions were similar to tangential-fields. ViTAT should allow automatic plan optimization by developing knowledge-based DVH prediction models of patients treated with tangential-fields. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
12. Integration of Diffusion Magnetic Resonance Tractography into tomotherapy radiation treatment planning for high-grade gliomas.
- Author
-
Altabella, Luisa, Broggi, Sara, Mangili, Paola, Conte, Gian Marco, Pieri, Valentina, Iadanza, Antonella, del Vecchio, Antonella, Anzalone, Nicoletta, di Muzio, Nadia, Calandrino, Riccardo, Falini, Andrea, and Castellano, Antonella
- Abstract
Highlights • White matter is more sensitive to radiation with respect to Gray matter. • MR-Tractography allows to identify the eloquent white matter tracts. • Integration of MR Tractography in Tomotherapy RT planning for brain tumors is investigated. Abstract Introduction Fractionated radiotherapy in brain tumors is commonly associated with several detrimental effects, largely related to the higher radiosensitivity of the white matter (WM) with respect to gray matter. However, no dose constraints are applied to preserve WM structures at present. Magnetic Resonance (MR) Tractography is the only technique that allows to visualize in vivo the course of WM eloquent tracts in the brain. In this study, the feasibility of integrating MR Tractography in tomotherapy treatment planning has been investigated, with the aim to spare eloquent WM regions from the dose delivered during treatment. Methods Nineteen high grade glioma patients treated with fractionated radiotherapy were enrolled. All the patients underwent pre-treatment MR imaging protocol including Diffusion Tensor Imaging (DTI) acquisitions for MR Tractography analysis. Bilateral tracts involved in several motor, language, cognitive functions were reconstructed and these fiber bundles were integrated into the Tomotherapy Treatment planning system. The original plans without tracts were compared with the optimized plans incorporating the fibers, to evaluate doses to WM structures in the two differently optimized plans. Results No significant differences were found between plans in terms of planning target volume (PTV) coverage between the original plans and the optimized plans incorporating fiber tracts. Comparing the mean as well as the maximal dose (Dmean and Dmax), a significant dose reduction was found for most of the tracts. The dose sparing was more relevant for contralateral tracts (P < 0.0001). Conclusion The integration of MR Tractography into radiotherapy planning is feasible and beneficial to preserve important WM structures without reducing the clinical goal of radiation treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. Knowledge-based plan optimization for prostate SBRT delivered with CyberKnife according to RTOG0938 protocol.
- Author
-
Monticelli, Davide, Castriconi, Roberta, Tudda, Alessia, Fodor, Andrei, Deantoni, Chiara, Gisella Di Muzio, Nadia, Mangili, Paola, del Vecchio, Antonella, Fiorino, Claudio, and Broggi, Sara
- Abstract
• KB planning was applied to SBRT prostate cancer with CyberKnife. • The KB model generated DVH prediction for the bladder, the rectum and femoral heads. • A KB-based template was efficiently tuned for both sequential and VOLO algorithms. • The KB-model was able to generate high-quality automatic plans for both modalities. To extend the knowledge-based (KB) automatic planning approach to CyberKnife in the case of Stereotactic Body Radiation Therapy (SBRT) for prostate cancer. Seventy-two clinical plans of patients treated according to the RTOG0938 protocol (36.25 Gy/5fr) with CyberKnife were exported from the CyberKnife system to Eclipse to train a KB-model using the Rapid Plan tool. The KB approach provided dose-volume objectives for specific OARs only and not PTV. Bladder, rectum and femoral heads were considered in the model. The KB-model was successfully trained on 51 plans and then validated on 20 new patients. A KB-based template was tuned in the Precision system for both sequential optimization (SO) and VOLO optimization algorithms. Plans of the validation group were re-optimized (KB-TP) using both algorithms without any operator intervention and compared against the original plans (TP) in terms of OARs/PTV dose-volume parameters. Paired Wilcoxon signed-rank tests were performed to assess statistically significant differences (p < 0.05). Regarding SO, automatic KB-TP plans were generally better than or equivalent to TP plans. PTVs V95% was slightly worse while OARs sparing for KB-TP was significantly improved. Regarding VOLO optimization, the PTVs coverage was significantly better for KB-TP while there was a limited worsening in the rectum. A significant improvement was observed in the bladder in the range of low-intermediate doses. An extension of the KB optimization approach to the CyberKnife system has been successfully developed and validated in the case of SBRT prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
14. In Regard to Zureick et al.
- Author
-
Fodor, Andrei, Brombin, Chiara, Mangili, Paola, Fiorino, Claudio, and Di Muzio, Nadia
- Subjects
- *
RADIATION doses - Published
- 2022
- Full Text
- View/download PDF
15. Prostate-specific antigen percentage: An early predictive tool after iodine-125 interstitial brachytherapy for prostate cancer.
- Author
-
Paoluzzi, Mauro, Losa, Andrea, Cerboneschi, Valentina, Colosimo, Caterina, Fontana, Nicola, Mangili, Paola, Mignogna, Marcello, Nava, Luciano, and Ravaglia, Valentina
- Subjects
- *
PROSTATE cancer treatment , *INTERSTITIAL brachytherapy , *PROSTATE-specific antigen , *KAPLAN-Meier estimator , *THERAPEUTIC use of iodine - Abstract
Background After interstitial prostate iodine-125 brachytherapy (BT), prostate-specific antigen (PSA) evolution in time could predict overall biochemical relapse, but, considering the single patient, it is influenced by the presentation PSA amount and by the prostatic volume. It is also challenging to differentiate a PSA bounce from a biochemical relapse. Purpose To determine the usefulness of PSA percentage (PP) defined as the rate between PSA presented by a patient at time “t” and the PSA that the same patient had presented at the time of diagnosis (t0) assumed as 100% in predicting biochemical relapse and in differentiating them from PSA Bounces. Methods and Materials We included 721 patients from Milan S. Raffaele Turro (399) and Lucca Campo di Marte (then S. Luca) Hospital (322). The mean age of patients was 66.5 years (range, 50–79). Mean followup was 150 months (range, 24–180). For each patient, PSA was recorded before and after iodine-125 BT, and PPs were calculated. Cox regression model, relative operating characteristic curves, and Kaplan–Meier regression model were elaborated, and a cutoff of 20% was defined. Results We observed that PP >20% is an independent variable highly associated with relapse risk ( p < 0.0001) with a sensitivity of 79.7%, a specificity of 82%, and an hazard ratio of 12.1, since the 6 months of followup. A PSA increase above the nadir should be because of bounce (sensitivity and specificity of 81.4%, p < 0.0001) if patient had experienced at 6 months a PP <20%. Conclusions PP might represent an early and useful tool, predictive of clinical outcome in patients after BT for prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
16. Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy.
- Author
-
Fiorino, Claudio, Cozzarini, Cesare, Rancati, Tiziana, Briganti, Alberto, Cattaneo, Giovanni Mauro, Mangili, Paola, Di Muzio, Nadia Gisella, and Calandrino, Riccardo
- Published
- 2014
- Full Text
- View/download PDF
17. Sparing the penile bulb in the radical irradiation of clinically localised prostate carcinoma: A comparison between MRI and CT prostatic apex definition in 3DCRT, Linac-IMRT and Helical Tomotherapy
- Author
-
Perna, Lucia, Fiorino, Claudio, Cozzarini, Cesare, Broggi, Sara, Cattaneo, Giovanni Mauro, De Cobelli, Francesco, Mangili, Paola, Di Muzio, Nadia, and Calandrino, Riccardo
- Subjects
- *
DIAGNOSIS , *PROSTATE cancer , *PENIS abnormalities , *COMPARATIVE studies , *MAGNETIC resonance imaging of cancer , *CANCER tomography , *MEDICAL protocols , *IMPOTENCE , *CANCER radiotherapy - Abstract
Abstract: Background and purpose: To assess the impact of using MRI and Helical Tomotherapy (HT) compared to 3DCRT and dynamic IMRT on the dose to the penile bulb (PB). Materials and methods: Eight patients diagnosed with prostate cancer entered a treatment protocol including CT and MRI simulation. The prostate apex was defined on both MRI and CT. Treatment plans (HT, Linac-IMRT, 3DCRT and conventional technique), were elaborated on both MRI and CT images. A dose of 71.4Gy (2.55Gy/fraction) was prescribed; it was requested that PTVs be covered by 95% isodose line. The mean dose and V50 of PB were evaluated. Results: PTV-MRI plans reduced PB mean dose and V50 compared to PTV-CT plans. This improvement, deriving also from the treatment modality, was 89% for 3DCRT, 99% for Linac-IMRT and 97% for HT (p <0.01), considering V50. Conventional plans resulted in a significantly higher mean PB dose/V50 compared to 3DCRT-PTV-CT (+27%/+38%), Linac-IMRT-PTV-CT (+42%/+57%) and HT-PTV-CT (+32%/+48%) (p <0.01). The comparison between conventional and PTV-MRI techniques showed a still larger increase: +73%/+93% 3DCRT; +86%/+99% Linac-IMRT; +56%/+99% HT (p <0.01). The PB mean dose reduction with Linac-IMRT compared to 3DCRT was 24% (p =0.034) and 40% (p =0.027) for PTV-CT and PTV-MRI, respectively. This gain remained significant even when comparing Linac-IMRT to HT: 21% (p =0.07) PTV-CT and 68% (p =0.00002) PTV-MRI. HT was superior to 3DCRT with respect to PTV-CT (average gain 4%, p =0.044), whereas it resulted to be detrimental considering PTV-MRI (26Gy vs 16.5Gy), possibly due to the helical delivery of HT; however, in a patient where the distance bulb-PTV <1cm, HT provided better PB sparing than 3DCRT (29.5Gy vs 45.2Gy). Conclusions: MRI allowed efficient sparing of PB irrespective of the treatment modality. Linac-IMRT was shown to further reduce the dose to the bulb compared to 3DCRT and HT. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
18. Phase I–II Study of Hypofractionated Simultaneous Integrated Boost With Tomotherapy for Prostate Cancer
- Author
-
Di Muzio, Nadia, Fiorino, Claudio, Cozzarini, Cesare, Alongi, Filippo, Broggi, Sara, Mangili, Paola, Guazzoni, Giorgio, Valdagni, Riccardo, Calandrino, Riccardo, and Fazio, Ferruccio
- Subjects
- *
PROSTATE cancer treatment , *IMAGE-guided radiation therapy , *CANCER radiotherapy , *PHYSIOLOGICAL effects of radiation , *TARGET organs (Anatomy) , *SEMINAL vesicles , *HEALTH outcome assessment - Abstract
Purpose: To report planning and acute toxicity data of the first 60 patients treated within a Phase I–II study with moderate hypofractionation by image-guided helical tomotherapy. Methods and Materials: Various clinical target volumes (CTVs) were defined: CTV1—pelvic nodes; CTV2—upper portion of seminal vesicles; CTV3—lower portion of SV; CTV4—prostate; overlap between planning target volume (PTV) 4 and rectum. Different doses to each PTV were simultaneously delivered in 28 fractions. For 31 low-risk patients: 56.0, 61.6, and 71.4 Gy for PTV2–4, respectively; for 20 intermediate-risk patients: 51.8, 61.6, 65.5, and 74.2 Gy for PTV1–4, respectively; for 9 high-risk patients: 51.8 and 65.5 Gy for PTV1–2 and 74.2 Gy for PTV3–4. For all patients, the dose to overlap was 65.5 Gy. Results: The mean fraction of rectum receiving more than 65 Gy (V65) and rectal Dmax were 10% and 70.8 Gy respectively. In cases of pelvic node irradiation, the intestinal cavity (outside PTV) receiving > 45 and 50 Gy was 86 and 12 cc, respectively. A homogeneous dose distribution within each PTV was guaranteed. Acute genitourinary toxicity according to RTOG scoring system was as follows: 21/60 (35%) Grade 1, 12/60 (20%) Grade 2, 2/60 (3%) Grade 3. Acute rectal toxicities were: 18/60 (30%) Grade 1. Twelve (20%) patients showed Grade 1 upper intestinal toxicity (uGI). No patients experienced ≥ Grade 2 acute rectal or uGI side effects. Conclusions: This study shows excellent results with regard to acute toxicity. Further research is necessary to assess definitive late toxicity and tumor control outcome. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
19. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy
- Author
-
Salembier, Carl, Lavagnini, Pablo, Nickers, Philippe, Mangili, Paola, Rijnders, Alex, Polo, Alfredo, Venselaar, Jack, and Hoskin, Peter
- Subjects
- *
PROSTATE cancer , *RADIOISOTOPE brachytherapy , *MALE reproductive organs , *PHOTOGRAPHIC dosimetry - Abstract
Abstract: The aim of this paper is to supplement the GEC/ESTRO/EAU recommendations for permanent seed implantations in prostate cancer to develop consistency in target and volume definition for permanent seed prostate brachytherapy. Recommendations on target and organ at risk (OAR) definitions and dosimetry parameters to be reported on post implant planning are given. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
20. Salvage brachytherapy for local recurrence after radical prostatectomy and subsequent external beam radiotherapy
- Author
-
Losa, Andrea, Nava, Luciano Dante, Di Muzio, Nadia, Mangili, Paola, Longobardi, Barbara, Rigatti, Patrizio, and Guazzoni, Giorgio
- Subjects
- *
PROSTATECTOMY , *RADIOTHERAPY , *ONCOLOGY , *HISTOLOGY - Abstract
: ObjectivesTo evaluate the technical feasibility, safety, and efficacy of seed implantation for local recurrence after radical prostatectomy and external beam radiotherapy.: MethodsBetween October 1999 and March 2002, 10 patients with targeted, histologically proven local relapse after surgery and subsequent external beam radiotherapy (only in 8 patients), underwent permanent brachytherapy with palladium-103 and iodine-125 after complete restaging. In all patients, an intraoperative morphovolumetric ultrasound study of the target was performed, with a planning target volume ranging from 5 to 26.7 cm3. The preimplant prostate-specific antigen values ranged from 1.1 to 6.31 ng/mL.: ResultsPostplan dosimetry was performed to determine the percentage of the target volume that received a dose equal to, or greater than, the prescribed dose (range 84.5% to 95.9%) and the dose that was delivered to the 90% of the target volume (range 85.08% to 129.43%). The urinary scores, measured using the International Prostate Symptom Score, had normalized at 3 months. Only 1 patient had worsened incontinence during the first 2 months, with subsequent restoration of the previous situation. The other patients did not have any changes in their previous clinical condition. One patient experienced occasional gross hematuria that had been present after external beam radiotherapy. No rectal complications were reported. After a median follow-up of 20.6 months, 7 patients showed a decreasing or stable prostate-specific antigen level.Conclusions. This preliminary experience has demonstrated that seed implantation of a neoplastic local recurrence is technically feasible and safe and allows for accurate dosimetry when the area to be treated can be defined by ultrasonography. Longer follow-up, accurate patient selection, and larger series of patients could help to better define the oncologic outcome. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
21. Lethal pulmonary complications significantly correlate with individually assessed mean lung dose in patients with hematologic malignancies treated with total body irradiation
- Author
-
Volpe, Aldo Della, Ferreri, Andrés José Marıa, Annaloro, Claudio, Mangili, Paola, Rosso, Alberto, Calandrino, Riccardo, Villa, Eugenio, Lambertenghi-Deliliers, Giorgio, and Fiorino, Claudio
- Subjects
- *
PNEUMONIA , *BONE marrow transplantation - Abstract
Purpose : To assess the impact of lung dose on lethal pulmonary complications (LPCs) in a single-center group of patients with hematologic malignancies treated with total body irradiation (TBI) in the conditioning regimen for bone marrow transplantation (BMT).Methods : The mean lung dose of 101 TBI-conditioned patients was assessed by a thorough (1 SD around 2%) in vivo transit dosimetry technique. Fractionated TBI (10 Gy, 3.33 Gy/fraction, 1 fraction/d, 0.055 Gy/min) was delivered using a lateral-opposed beam technique with shielding of the lung by the arms. The median lung dose was 9.4 Gy (1 SD 0.8 Gy, range 7.8–11.4). The LPCs included idiopathic interstitial pneumonia (IIP) and nonidiopathic IP (non-IIP).Results : Nine LPCs were observed. LPCs were observed in 2 (3.8%) of 52 patients in the group with a lung dose ≤9.4 Gy and in 7 (14.3%) of 49 patients in the >9.4 Gy group. The 6-month LPC risk was 3.8% and 19.2% (p = 0.05), respectively. A multivariate analysis adjusted by the following variables: type of malignancy (acute leukemia, chronic leukemia, lymphoma, myeloma), type of BMT (allogeneic, autologous), cytomegalovirus infection, graft vs. host disease, and previously administered drugs (bleomycin, cytarabine, cyclophosphamide, nitrosoureas), revealed a significant and independent association between lung dose and LPC risk (p = 0.02; relative risk = 6.7). Of the variables analyzed, BMT type (p = 0.04; relative risk = 6.6) had a risk predictive role.Conclusion : The mean lung dose is an independent predictor of LPC risk in patients treated with the 3 × 3.33-Gy low-dose-rate TBI technique. Allogeneic BMT is associated with a higher risk of LPCs. [Copyright &y& Elsevier]- Published
- 2002
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.